This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

PharmaFocus: Vaccine Adjuvants In Infectious Disease

6.3.2 Combinatorial Adjuvant Systems 61

6.3.3 Limited Use of Antigen Depot 61

7 Clinical Trials and Regulatory Strategy 63

7.1 Clinical Trial Design 63

7.1.1 Non-clinical Evaluation 63

7.1.2 Adjuvant Mechanism of Action Evaluation 64

7.1.3 Clinical Safety Evaluation 64

7.1.4 KOL Opinion on Clinical Design 65

7.2 Regulatory Strategy 67

7.2.1 Overview 67

7.2.2 World Health Organization (WHO) 68

7.2.3 US 69

7.2.4 EU 73

7.2.5 Cultural Differences in Adjuvant Use (US vs. Europe) 73

8 Appendix 75

8.1 Bibliography 75

8.2 Abbreviations 81

8.3 Research Methodology 82

8.4 Physicians and Specialists Included in this Study 83

8.5 About the Authors 85

8.5.1 Author 85

8.5.2 Reviewer 85

8.5.3 Global Head of Healthcare 86

8.6 About GlobalData 86

8.7 Contact Us 86

8.8 Disclaimer 87

List of Tables

Table 1: Primary Physical (Epithelial) Barriers to Infection 12

Table 2: Immune Cells and Their Corresponding Toll-like Receptors 15

Table 3: TLR Adjuvant Targets and Ligand Types in Clinical Trials for Infectious Disease Vaccines 24

Table 4: Vaccine Adjuvants – Drivers and Barriers, 2013 27

Table 5: Leading Adjuvants in Clinical Trials for Human Infectious Disease Vaccines 36

Table 6: Product Profile – Aluminum Salts/Alum 38

Table 7: Aluminum Salts/Alum SWOT Analysis, 2013 40

Table 8: Product Profile – Emulsions 42

Table 9: Emulsions SWOT Analysis, 2013 43

Table 10: Product Profile – Particulate Delivery Mechanisms 45

Table 11: Particulate Delivery Mechanisms SWOT Analysis, 2013 46

Table 12: Product Profile – Microbial Derivatives 48

Table 13: Microbial Derivatives SWOT Analysis, 2013 49

Table 14: Product Profile – Oligonucleotides 50

Table 15: Oligonucleotides SWOT Analysis, 2013 52

Table 16: Product Profile – Adjuvant Systems 53

Table 17: GSK's Adjuvant System Portfolio, 2013 53

Table 18: Adjuvant Systems SWOT Analysis, 2013 55

Table 19: Overall Unmet Needs – Current Level of Attainment 56

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,065.78 -137.59 -0.76%
S&P 500 2,095.95 -11.83 -0.56%
NASDAQ 4,962.92 -16.9810 -0.34%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs